-
Targeting difficult-to-drug targets US$50 million to help develop next-generation small molecule discovery platforms
Time of Update: 2021-09-13
Jnana's pilot project aims to reduce the level of Phe in the blood that drives the pathology of PKU disease by inhibiting SLC6A19, so as to provide a new oral small molecule therapy for the treatment of PKU .
Retrieved August 18, 2021, from https:// therapeutics-closes-50-million-series-b-financing-to-advance-lead-pku-program-and-small-molecule-pipeline-based-on-next-gen-chemoproteomic-platform/
-
Song Ruilin, President of China Pharmaceutical Promotion Association: Determine the price of innovative drugs based on clinical value and determine the payment ratio according to the ability to pay
Time of Update: 2021-09-12
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, said in an interview with a reporter from Chinanet.
" Song Ruilin suggested "It is not to let medical insurance be fully supported, but the price must be determined by clinical value and its comprehensive social value.
-
First-line treatment of gastric cancer, Zai Lab introduces new monoclonal antibody to treat breakthrough treatment
Time of Update: 2021-09-12
Bemarituzumab domestic project progress From: Insight database In November last year, in the Phase II clinical FIGHT study for the first-line treatment of gastric and gastroesophageal junction cancer (GEJ), bemarituzumab successfully reached the three efficacy endpoints of PFS, OS and ORR .
-
Semi-annual report of Tianjing Bio: will submit a CD38 antibody listing application and start the research and development of "super antibody"
Time of Update: 2021-09-12
At the same time, the company's product pipeline has achieved 13 key R&D milestones, and is expected to submit a new drug listing application for the CD38 antibody fezetuzumab (TJ202) to the China National Medical Products Administration (NMPA) in the fourth quarter of this year .
-
CStone Pharmaceuticals shares are officially included in Southbound Trading
Time of Update: 2021-09-12
(Suzhou, China, September 6, 2021) CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focused on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, announced today that the company The stock was officially included in the Southbound Stock Connect list and became effective on the same day .
-
Hengrui Medicine's 76 new class 1 new drugs, 15 varieties, are the first to imitate 20 varieties, and the first to be reviewed
Time of Update: 2021-09-12
In the field of anti-tumor, SHR6390 tablets (CDK4/6 selective inhibitor) have been declared for the market, and are expected to become the first domestically produced CDK4/6 inhibitor class 1 new drug; famitinib malate capsules (multi-target tyrosine kinase inhibitor) ), SHR3680 tablets (androgen receptor antagonist), SHR-1316 injection (PD-L1 monoclonal antibody) and other Class 1 new drugs are undergoing phase III clinical trials, and the research and development progress is ahead of other domestic companies in research .
-
"Price war" alternative play: retrograde high price strategy in the context of centralized procurement
Time of Update: 2021-09-12
However, there are also some original research brand drugs in the OTC channel (including online pharmacies and offline pharmacies) sales volume and sales amount is not significantly lower than before the centralized procurement, one of the important reasons is that their prices are relatively "friendly to the people", consumption The consumers have accepted or recognized their prices.
-
Turbulent Five Years: China's Pharmaceutical Industry "Thirteenth Five-Year Plan" Retrospective Analysis-Market Chapter
Time of Update: 2021-09-12
During the "13th Five-Year Plan" period, the market structure of China's pharmaceutical industry has undergone significant changes . What are the underlying reasons for these changes? Which aspects
-
The FDA has accelerated its approval, and Novartis, AstraZeneca, Roche, etc. are optimistic, and "alternative" conjugate drugs are on the rise!
Time of Update: 2021-09-12
On February 26, the biopharmaceutical company Oncopeptides announced that the FDA has accelerated the approval of its PDC drug Pepaxto (melphalan flufenamide, also known as melflufen) to be marketed for use in combination with dexamethasone.
-
US FDA approves Baiyueze® (Zebutinib) for the treatment of patients with Waldenstrom's macroglobulinemia
Time of Update: 2021-09-12
Steven Treon, Director of the Fahrenheit Macroglobulinemia Research Bing Center and Professor of Medicine at Harvard Medical School at the Dana-Farber Cancer Institute in the United States, commented: A highly active inhibitor for the treatment of patients with Waldenstrom's macroglobulinemia, compared with the first-generation BTK inhibitor, it has shown better tolerance in a series of clinically important side effects .
-
Hospital alliance procurement is on!
Time of Update: 2021-09-12
In addition to centralized procurement at the national and provincial levels, varieties with mature technology, clinically necessary, and high value After the alliance procurement results are reported to the Provincial Medical Insurance Bureau by the Alliance Procurement Office, they will be listed on the provincial pharmaceutical procurement platform according to the procedures .
-
2 Class 1 new drugs and 3 first imitations have been approved!
Time of Update: 2021-09-12
SummarySummary In August, CDE undertook a total of 1090 drug registration applications For the first time, the 8 stock varieties have the consistency evaluation of the enterprise declaration Kangfang Biological submits another application for the marketing of Paimrizumab injection There are 15 types of imitation applications, and 1 type of import applications has not been approved for domestic use.
-
Enter the expert review stage!
Time of Update: 2021-09-12
Recently, the National Medical Insurance Administration issued an announcement that the list of declared drugs announced at the beginning of this month has been reviewed and revised, and the results of the review of the 2021 National Medical Insurance Drug List adjustment form have been formally formed .
-
2021H1 cell therapy financing exceeds 7.3 billion U.S. dollars: T cell and stem cell therapies occupy high ground, NK cell therapy has become a new trend, spot-type therapy is worthy of attention
Time of Update: 2021-09-12
Not long after the Series A financing stepped out of the stealth mode, Appia Bio reached a cooperation and licensing agreement with Kite, a company of Gilead Sciences, on August 5 to use the former "ACUA" allogeneic cell therapy technology platform to develop Constant natural killer T cell (CAR-iNKT) therapy expressing chimeric antigen receptors is used for cancer .
-
Over 4 billion U.S. dollars!
Time of Update: 2021-09-12
Drug name: TAZVERIKDrug name: Authorized party: EpizymeAuthorized party: Introducer: Hutchison MedicineIntroducing party: On August 9, Hutchison Pharmaceuticals announced that it has reached a cooperation with Epizyme to conduct research, development, production and commercialization of TAZVERIK in Greater China (including China, Hong Kong, Macau and Taiwan) .
-
PDB's in-depth interpretation: The pharmaceutical market in the whole field shines, with an increase of 17.9% and a new high!
Time of Update: 2021-09-12
Figure 1 2012-2021 Q2 analysis of sales growth of sample hospitals in key cities in my country We analyze the various treatment markets according to the ATC classification.
21 billion yuan, while the total revenue of five Chinese companies is 13.
-
2021 drug delivery half-process combing
Time of Update: 2021-09-12
It can be seen from the national volume procurement and provincial-level projects over the years that the thinking of the centralized drug procurement organization is gradually changing from low prices to ensuring supply at reasonable prices, especially when the price of chemical medicines is increased to a certain level.
-
Cinda Bio and Jinfang Pharmaceutical reached a global strategic cooperation on GFH925 (KRAS G12C inhibitor)
Time of Update: 2021-09-12
Cinda biological as exclusive partnership with obtaining drug candidates targeting a --GFH925 strength and western medicine is common in lung cancer and other solid tumors, cancer-causing gene KRAS G12C the drive (KRAS G12C inhibitors) in China (including mainland China, Hong Kong, Macau and Taiwan) development and commercialization rights, and have the right to choose global development and commercialization rights .
-
The BMS-Pfizer Alliance lawsuit wins!
Time of Update: 2021-09-12
Over the years, BMS and Pfizer have also been working hard to fight against generic drug manufacturers .
For example, in 2017, the two parties initiated patent infringement lawsuits against as many as 25 companies that applied for US FDA approval of their generic drugs .
-
The PI3Kδ inhibitor introduced by Innovent starts Phase 3 clinical trials in China
Time of Update: 2021-09-12
The latest announcement on the Chinese drug clinical trial registration and information disclosure platform, the PI3Kδ inhibitor parsaclisib tablets introduced by Indah Biologics Incyte, has initiated a phase 3 international multi-center clinical study for the treatment of subjects with myelofibrosis .
